Anti-activated factor × response to enoxaparin in critically ill patients
| Autor: | Moshe Hersch, D Shemesh, D Bitran, M Naamad, Shoshana Zevin, Sharon Einav, I Dezigibker |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
medicine.medical_specialty
Critically ill business.industry medicine.drug_class Deep vein Low molecular weight heparin Post injection Critical Care and Intensive Care Medicine medicine.disease Thrombosis medicine.anatomical_structure Antithrombotic Poster Presentation medicine Dosing Intensive care medicine business |
| Zdroj: | Critical Care |
| ISSN: | 1466-609X 1364-8535 |
| Popis: | Low molecular weight heparin (LMWH) dosing protocols for deep vein thrombosis prophylaxis in critically ill patients (CIPs) are not based on pharmacologic studies in these patients. Antithrombotic LMWH activity correlates with peak anti-activated factor × (aFXa) levels (4 hours post injection) of 0.1 to 0.2 IU/ml. The hypothesis of this study is that most CIPs do not achieve therapeutic levels for prevention of DVT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink